非小細胞肺がん（NSCLC）市場は、世界的に肺がんの総数が増加していることによって生み出される機会を背景に成長が予想されており、そのうち非小細胞肺がん（NSCLC）が大きなシェアを占めています。このため、主要なリーダーの大多数は、治療法の進歩と既存の治療法の効率向上に注力するようになりました。この市場は、最も広く発生している疾患としての肺がんの現状と、それによる死亡者数の増加も推進要因になっています。また、研究開発における主要リーダーによる投資の増加と、主要な市場プレーヤーへの非小細胞肺がん（NSCLC）治療薬の導入によって、世界的に市場が押し上げられています。
目次
1. Executive Summary
2. Non-Small Cell Lung Cancer (NSCLC)
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix
7. Recent Development, Policies&Regulatory Landscape
8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. Non-Small Cell Lung Cancer (NSCLC) Industry Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Global Non-Small Cell Lung Cancer (NSCLC) Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. Global Non-Small Cell Lung Cancer (NSCLC) Market: Market Segmentation
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2. By Histology Market Share (2020-2030F)
11.2.1. Large cells carcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2.2. Adenocarcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2.3. SCC or Squamous cell, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3. By Treatment: Market Share (2020-2030F)
11.3.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.2. Radiation, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.3. Surgery, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. Company Profile
12.1. Rozlytrek (Entrectinib): Hofmann -La Roche
12.1.1. Company Overview
12.1.2. Company Total Revenue (Financials)
12.1.3. Market Potential
12.1.4. Global Presence
12.1.5. Key Performance Indicators
12.1.6. SWOT Analysis
12.1.7. Product Launch
12.2. Opdivo (Nivolumab): Bristol-Myers Squibb
12.3. Tagrisso (Osimertinib): AstraZeneca
12.4. Vizimpro (Dacomitinib): Pfizer
12.5. Portrazza (Nacitumumab): Eli Lilly and Company
12.6. Imfinzi (Durvalumab): AstraZeneca.
12.7. Vitrakvi (Larotrectinib): Bayer Healthcare
12.8. Other Prominent Players
Consultant Recommendation
The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
